Guideline Summary NGC (2016): Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Journal Title: Нирки - Year 2016, Vol 4, Issue 18
Abstract
National Institute for Health and Care Excellence (NICE) June 14, 2016 – Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) External Web Site Policy: The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Based on recent reports, they have revised the warnings in the drug labels to include information about acute kidney injury and added recommendations to minimize this risk.
Authors and Affiliations
Mariia Ivanova
Keywords
Related Articles
- EP ID EP207144
- DOI 10.22141/2307-1257.4.18.2016.84326
- Views 96
- Downloads 0
Diabetic Nephropathy and Nutritional Therapy
.
Kidney Transplantation on Children
.
The Use of Extracts of Goldenrod (Solidago Virgaurea L.) for the Treatment of Diseases of the Urinary Tract
This review examines the pharmacological and clinical data on the use of extracts of goldenrod (Solidago virgaurea L.) for the treatment of diseases of the urinary system. Goldenrod extracts exhibit 6 major pharmacologic...
Comparative evaluation of uricodepressants allopurinol and febuxostat in gouty nephropathy. Message 2. Еxperimental study
Background. In our previous study (message 1), a comparative evaluation on the efficacy of two uricodepressants, allopurinol and febuxostat, was performed in terms of their effect on the functional state of the kidneys i...
Renin-Angiotensin System Blockers and Renal Functional Reserve. Is There a Limit of Renoprotection?
Renin-angiotensin system (RAS) blockers (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, direct renin inhibitor) have a renoprotective effect in the presence of preserved glomerular filtration ra...